TriSalus Life Sciences and the University of Texas today announced a collaboration to evaluate the treatment of solid tumors. The Texas MD Anderson Cancer Center and TriSalus will collaborate on treatments for tumors of the pancreas and liver by integrating interventional delivery of SD-101, an investigational toll-like receptor 9 (TLR9) agonist, in combination with checkpoint inhibition […]
University of Texas
FDA clears Nanobiotix to start cancer treatment trial
Nanobiotix (PAR:NANO.PA) announced that the FDA designated its cancer treatment trial with the University of Texas MD Anderson Cancer Center as “safe to proceed.” The trial, co-developed by Nanobiotix and MD Anderson, is set to evaluate the safety and feasibility of NBTXR3 activated-by-radiation therapy for patients with locally advanced (LAPC) or borderline resectable (BRPC) cases of […]
This molecule stops pancreatic cancer cells from spreading
Wake Forest Baptist Medical Center scientists have identified molecules that could be the next therapeutic solution for pancreatic cancer. Pancreatic cancer is one of the most lethal forms of cancer. About 53,670 people are expected to be diagnosed with pancreatic cancer this year with 43,090 dying from it, according to the American Cancer Society. The lifetime […]